Peter Stock, MD

Transplant surgeon

Dr. Peter Stock is a transplant surgeon who specializes in kidney, liver and pancreas transplants and is co-director of the Pancreatic Islet Cell Transplant Program. Stock was trained at the University of Minnesota, completing a surgical internship and residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992.

Stock is an active teacher and supervises surgical residents and fellows. He is a member of numerous professional and honorary societies. In his research, he studies the mechanisms of allograft rejection, chimerism (anti-rejection therapy using the donor's bone marrow cells) and pancreatic islet cell transplantation.

Clinics

Connie Frank Transplant Center at UCSF
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Pre-Kidney Fax: (415) 353-8708
Post-Kidney Fax: (415) 353-8381

Hours: 8 a.m. – 5 p.m.

Liver Transplant Program
400 Parnassus Ave., Third Floor
San Francisco, CA 94143
Phone: (415) 353-1888
Fax: (415) 353-8917

Hours: Tuesdays, 8 a.m. – noon, and Thursdays, 1 - 4 p.m.

Pancreas Transplant Services
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Pre-Transplant Fax: (415) 353-8708
Post-Transplant Fax: (415) 353-4183

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Board Certification

Surgery, American Board of Surgery

Academic Title

Professor

More about Peter Stock

Education

University of Illinois School of Medicine 1982

Residencies

University of Minnesota Medical Center, General Surgery 1990

Fellowships

UCSF Medical Center, Transplant Surgery 1992

Selected Research and Publications

  1. Rickels MR, Stock PG, de Koning EJP, Piemonti L, Pratschke J, Alejandro R, Bellin MD, Berney T, Choudhary P, Johnson PR, Kandaswamy R, Kay TWH, Keymeulen B, Kudva YC, Latres E, Langer RM, Lehmann R, Ludwig B, Markmann JF, Marinac M, Odorico JS, Pattou F, Senior PA, Shaw JAM, Vantyghem MC, White S. Defining outcomes for -cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop. Transpl Int. 2018 Apr; 31(4):343-352.
  2. Rickels MR, Stock PG, de Koning EJP, Piemonti L, Pratschke J, Alejandro R, Bellin MD, Berney T, Choudhary P, Johnson PR, Kandaswamy R, Kay TWH, Keymeulen B, Kudva YC, Latres E, Langer RM, Lehmann R, Ludwig B, Markmann JF, Marinac M, Odorico JS, Pattou F, Senior PA, Shaw JAM, Vantyghem MC, White S. Defining Outcomes for -Cell Replacement Therapy in the Treatment of Diabetes: a Consensus Report on the Igls Criteria from the IPITA/EPITA Opinion Leaders Workshop. Transplantation. 2018 Mar 09.
  3. Piemonti L, de Koning EJP, Berney T, Odorico JS, Markmann JF, Stock PG, Rickels MR. Defining outcomes for beta cell replacement therapy: a work in progress. Diabetologia. 2018 Mar 06.
  4. Kandaswamy R, Stock PG, Gustafson SK, Skeans MA, Curry MA, Prentice MA, Fox A, Israni AK, Snyder JJ, Kasiske BL. OPTN/SRTR 2016 Annual Data Report: Pancreas. Am J Transplant. 2018 Jan; 18 Suppl 1:114-171.
  5. Stock PG. Strengths and weaknesses of using SRTR data to shape the management of the HIV-infected kidney transplant recipient. Am J Transplant. 2017 Dec; 17(12):3001-3002.
  6. Harbell JW, Morgan T, Feldstein VA, Roll GR, Posselt A, Kang SM, Feng S, Hirose R, Freise CE, Stock P. Splenic Vein Thrombosis Following Pancreas Transplantation: Identification of Factors That Support Conservative Management. Am J Transplant. 2017 Nov; 17(11):2955-2962.
  7. Newell KA, Mehta AK, Larsen CP, Stock PG, Farris AB, Mehta SG, Ikle D, Armstrong B, Morrison Y, Bridges N, Robien M, Mannon RB. Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept. Am J Transplant. 2017 Oct; 17(10):2712-2719.
  8. O'Connell PJ, Kuypers DR, Mannon RB, Abecassis M, Chadban SJ, Gill JS, Murphy B, Nickerson PW, Schold JD, Stock PG, Seron D, Alloway RR, Bromberg JS, Budde K, Jordan SC, Legendre C, Lefaucheur C, Sarwall M, Segev DL, Stegall MD, Tullius SG, Wong G, Woodle ES, Ascher N, Morris RE. Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction. Transplantation. 2017 07; 101(7):1527-1534.
  9. Ricordi C, Goldstein JS, Balamurugan AN, Szot GL, Kin T, Liu C, Czarniecki CW, Barbaro B, Bridges ND, Cano J, Clarke WR, Eggerman TL, Hunsicker LG, Kaufman DB, Khan A, Lafontant DE, Linetsky E, Luo X, Markmann JF, Naji A, Korsgren O, Oberholzer J, Turgeon NA, Brandhorst D, Friberg AS, Lei J, Wang LJ, Wilhelm JJ, Willits J, Zhang X, Hering BJ, Posselt AM, Stock PG, Shapiro AMJ. Erratum. National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes 2016;65:3418-3428. Diabetes. 2017 09; 66(9):2531.
  10. Wisel SA, Gardner JM, Roll GR, Harbell J, Freise CE, Feng S, Kang SM, Hirose R, Kaufman DB, Posselt AM, Stock PG. Pancreas-After-Islet Transplantation in Nonuremic Type 1 Diabetes: A Strategy for Restoring Durable Insulin Independence. Am J Transplant. 2017 Sep; 17(9):2444-2450.
  11. Ragni MV, Humar A, Stock PG, Blumberg EA, Eghtesad B, Fung JJ, Stosor V, Nissen N, Wong MT, Sherman KE, Stablein DM, Barin B. Hemophilia Liver Transplantation Observational Study. Liver Transpl. 2017 Jun; 23(6):762-768.
  12. Kandaswamy R, Stock PG, Gustafson SK, Skeans M, Thompson B, Kasiske BL. Reply to Comment on the Article "OPTN/SRTR 2015 Annual Data Report: Pancreas". Am J Transplant. 2017 Jul; 17(7):1954-1955.
  13. Chandran S, Stock PG. Opportunities and Challenges for Kidney Donation from and to HIV-Positive Individuals. Clin J Am Soc Nephrol. 2017 03 07; 12(3):385-387.
  14. Hart A, Gustafson SK, Skeans MA, Stock P, Stewart D, Kasiske BL, Israni AK. OPTN/SRTR 2015 Annual Data Report: Early effects of the new kidney allocation system. Am J Transplant. 2017 01; 17 Suppl 1:543-564.
  15. Kandaswamy R, Stock PG, Gustafson SK, Skeans MA, Curry MA, Prentice MA, Israni AK, Snyder JJ, Kasiske BL. OPTN/SRTR 2015 Annual Data Report: Pancreas. Am J Transplant. 2017 01; 17 Suppl 1:117-173.
  16. Roll GR, Stock PG. Strategies to improve outcomes for hepatitis C virus/human immunodeficiency virus coinfected liver transplant candidates. Liver Transpl. 2016 09; 22(9):1181-2.
  17. Stegall MD, Stock PG, Andreoni K, Friedewald JJ, Leichtman AB. Why do we have the kidney allocation system we have today? A history of the 2014 kidney allocation system. Hum Immunol. 2017 Jan; 78(1):4-8.
  18. Campos-Varela I, Dodge JL, Stock PG, Terrault NA. Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus. Clin Transplant. 2016 Sep; 30(9):1140-5.
  19. Wisel SA, Braun HJ, Stock PG. Current outcomes in islet versus solid organ pancreas transplant for -cell replacement in type 1 diabetes. Curr Opin Organ Transplant. 2016 Aug; 21(4):399-404.
  20. Ricordi C, Goldstein JS, Balamurugan AN, Szot GL, Kin T, Liu C, Czarniecki CW, Barbaro B, Bridges ND, Cano J, Clarke WR, Eggerman TL, Hunsicker LG, Kaufman DB, Khan A, Lafontant DE, Linetsky E, Luo X, Markmann JF, Naji A, Korsgren O, Oberholzer J, Turgeon NA, Brandhorst D, Chen X, Friberg AS, Lei J, Wang LJ, Wilhelm JJ, Willits J, Zhang X, Hering BJ, Posselt AM, Stock PG, Shapiro AM, Chen X. National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes. 2016 11; 65(11):3418-3428.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.